Chemomab Therapeutics (CMMB) Assets (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Assets came in at $13.8 million in Q4 2025, down 18.58% YoY from $17.0 million in Q4 2024, and up 11.68% on a QoQ basis from $12.4 million in Q3 2025.
Chemomab Therapeutics (CMMB) Assets (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Assets data on file, last reported at $13.8 million in Q4 2025.
- Quarterly Assets fell 18.58% year-over-year to $13.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.8 million (down 18.58% YoY) and the FY2025 annual result came in at $13.8 million, down 18.58% from the prior year.
- Assets improved to $13.8 million in Q4 2025, from $12.4 million in the prior quarter.
- In the past five years, Assets ranged from a high of $70.5 million in Q2 2021 to a low of $11.1 million in Q2 2025.
- A 5-year average of $35.2 million and a median of $26.1 million in 2023 frame the typical range for Assets.
- Annual changes were most pronounced in 2021 — Assets jumped 777.1% — and 2023, when it tumbled 53.37%.
- Tracing CMMB's Assets over 5 years: stood at $64.4 million in 2021, then tumbled by 33.08% to $43.1 million in 2022, then slumped by 48.56% to $22.2 million in 2023, then fell by 23.42% to $17.0 million in 2024, then fell by 18.58% to $13.8 million in 2025.
- The last three Assets figures came in at $13.8 million (Q4 2025), $12.4 million (Q3 2025), and $11.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 13.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.81 Mn |
| Sep 30, 2025 | 12.37 Mn |
| Jun 30, 2025 | 11.13 Mn |
| Mar 31, 2025 | 12.82 Mn |
| Dec 31, 2024 | 16.96 Mn |
| Sep 30, 2024 | 20.90 Mn |
| Jun 30, 2024 | 14.54 Mn |
| Mar 31, 2024 | 18.01 Mn |
| Dec 31, 2023 | 22.15 Mn |
| Sep 30, 2023 | 23.42 Mn |
| Jun 30, 2023 | 28.85 Mn |
| Mar 31, 2023 | 35.01 Mn |
| Dec 31, 2022 | 43.06 Mn |
| Sep 30, 2022 | 50.22 Mn |
| Jun 30, 2022 | 56.38 Mn |
| Mar 31, 2022 | 60.96 Mn |
| Dec 31, 2021 | 64.35 Mn |
| Sep 30, 2021 | 67.44 Mn |
| Jun 30, 2021 | 70.52 Mn |
| Mar 31, 2021 | 60.12 Mn |